


BAY 60-2770

Cat. No.:	HY-113926
CAS No.:	1027642-43-8
Molecular Formula:	C ₃₅ H ₃₃ F ₄ NO ₅
Molecular Weight:	623.63
Target:	Guanylate Cyclase
Pathway:	GPCR/G Protein
Storage:	4°C, sealed storage, away from moisture and light * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)



SOLVENT & SOLUBILITY

In Vitro

DMSO : 16.67 mg/mL (26.73 mM; Need ultrasonic)

Concentration	Solvent	Mass		
		1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM	1.6035 mL	8.0176 mL	16.0351 mL
	5 mM	0.3207 mL	1.6035 mL	3.2070 mL
	10 mM	0.1604 mL	0.8018 mL	1.6035 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

BAY 60-2770 is a potent, selective, and orally active soluble guanylyl cyclase (sGC) activator. BAY 60-2770 increases the activity of sGC in a nitric oxide-independent manner. BAY 60-2770 shows antifibrotic effect^{[1][2]}.

In Vivo

BAY 60-2770 (0.1-0.3 mg/Kg; p.o.) attenuates liver fibrosis in two rat models^[1].

BAY 60-2770 (1 mg/kg; p.o.; daily from the 10th to the 12th week) results in amelioration of bladder dysfunction in high-fat obese mice^[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Obese mice ^[2]
Dosage:	1 mg/kg
Administration:	p.o.; daily from the 10th to the 12th week
Result:	Ameliorates detrusor dysfunction in obese mice.

REFERENCES

- [1]. Knorr A, et al. Nitric oxide-independent activation of soluble guanylate cyclase by BAY 60-2770 in experimental liver fibrosis. *Arzneimittelforschung*. 2008;58(2):71-80.
- [2]. Leiria LO, et al. The soluble guanylyl cyclase activator BAY 60-2770 ameliorates overactive bladder in obese mice. *J Urol*. 2014 Feb;191(2):539-47.
-

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA